X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (677) 677
middle aged (515) 515
female (509) 509
male (485) 485
antineoplastic combined chemotherapy protocols - therapeutic use (453) 453
aged (438) 438
adult (423) 423
antineoplastic combined chemotherapy protocols - adverse effects (370) 370
vindesine (334) 334
vindesine - administration & dosage (326) 326
lung neoplasms - drug therapy (302) 302
cisplatin - administration & dosage (290) 290
oncology (278) 278
carcinoma, non-small-cell lung - drug therapy (209) 209
vinblastine - analogs & derivatives (199) 199
vindesine - adverse effects (178) 178
chemotherapy (155) 155
vinblastine - administration & dosage (147) 147
vinblastine - adverse effects (147) 147
cisplatin - adverse effects (138) 138
treatment outcome (129) 129
survival rate (124) 124
cisplatin (123) 123
drug administration schedule (120) 120
drug evaluation (115) 115
combined modality therapy (99) 99
lung neoplasms - pathology (99) 99
neoplasm staging (97) 97
vinblastine - therapeutic use (90) 90
carcinoma, non-small-cell lung - pathology (89) 89
doxorubicin - administration & dosage (89) 89
lung neoplasms - mortality (89) 89
cyclophosphamide - administration & dosage (87) 87
remission induction (86) 86
adolescent (81) 81
survival analysis (79) 79
etoposide - administration & dosage (78) 78
antineoplastic agents - adverse effects (75) 75
carcinoma, squamous cell - drug therapy (71) 71
bleomycin - administration & dosage (70) 70
carcinoma, non-small-cell lung - mortality (70) 70
combination chemotherapy (69) 69
vindesine - therapeutic use (68) 68
prognosis (67) 67
antineoplastic combined chemotherapy protocols - administration & dosage (66) 66
cancer (65) 65
antineoplastic agents - therapeutic use (62) 62
carcinoma (61) 61
vincristine - administration & dosage (61) 61
prospective studies (60) 60
ifosfamide - administration & dosage (58) 58
randomized trial (57) 57
leukopenia - chemically induced (55) 55
mitomycin (55) 55
mitomycin - administration & dosage (55) 55
trial (54) 54
survival (53) 53
breast neoplasms - drug therapy (52) 52
neoplasm metastasis (52) 52
therapy (52) 52
adenocarcinoma - drug therapy (51) 51
vinorelbine (51) 51
non-small cell lung cancer (50) 50
clinical trials as topic (49) 49
disease-free survival (49) 49
mitomycins - administration & dosage (49) 49
prednisone - administration & dosage (49) 49
antineoplastic agents - administration & dosage (48) 48
follow-up studies (47) 47
index medicus (46) 46
time factors (46) 46
pharmacology & pharmacy (44) 44
bleomycin - adverse effects (43) 43
lung neoplasms - radiotherapy (43) 43
melanoma - drug therapy (43) 43
radiotherapy (43) 43
respiratory system (43) 43
combination (42) 42
etoposide (42) 42
hematology (42) 42
cyclophosphamide - adverse effects (39) 39
antineoplastic agents, phytogenic - administration & dosage (38) 38
carcinoma, small cell - drug therapy (38) 38
phase-ii (38) 38
antineoplastic agents, phytogenic - adverse effects (37) 37
carcinoma, non-small-cell lung - radiotherapy (37) 37
dose-response relationship, drug (36) 36
neutropenia - chemically induced (36) 36
vinblastine (35) 35
doxorubicin - adverse effects (34) 34
lung neoplasms - therapy (34) 34
methotrexate - administration & dosage (34) 34
carboplatin (33) 33
cisplatin - therapeutic use (33) 33
drug therapy, combination (33) 33
etoposide - adverse effects (33) 33
lung cancer (33) 33
lung cancer, non-small cell (33) 33
non-small-cell lung cancer (32) 32
antineoplastic agents, phytogenic - therapeutic use (31) 31
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (608) 608
Japanese (49) 49
French (26) 26
German (15) 15
Chinese (7) 7
Spanish (4) 4
Italian (3) 3
Polish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 06/2015, Volume 169, Issue 5, pp. 672 - 682
Summary This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐CC chemokine receptor 4... 
mogamulizumab | randomized phase II study | CCR4 | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | Randomized phase II study | adult T-cell leukaemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | RECEPTOR | LEUKEMIA/LYMPHOMA | HEMATOLOGY | EXPRESSION | ASSOCIATION | TRANSPLANTATION | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Haematological Malignancy | Research Paper
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 13, pp. 1287 - 1295
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2013, Volume 24, Issue 4, pp. 1032 - 1037
Journal Article
Blood, ISSN 0006-4971, 12/2003, Volume 102, Issue 13, pp. 4284 - 4289
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1136 - 1143
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2001, Volume 113, Issue 2, pp. 375 - 382
Journal Article
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 03/2012, Volume 53, Issue 3, pp. 406 - 410
Abstract Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1... 
GSTT1 | polymorphism | GSTM1 | prognosis | Hodgkin's lymphoma | Prognosis | Polymorphism | SUSCEPTIBILITY | RISK | ACUTE MYELOID-LEUKEMIA | CANCER | CHEMOTHERAPY | GENOTYPES | THERAPY | ONCOLOGY | DISEASE | HEMATOLOGY | ASSOCIATION | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Humans | Middle Aged | Biotransformation - genetics | Male | Carboplatin - pharmacokinetics | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Carboplatin - adverse effects | Anemia - genetics | Glutathione Transferase - physiology | Gene Deletion | Hodgkin Disease - mortality | Vincristine - administration & dosage | Neoplasm Proteins - genetics | Glutathione S-Transferase pi - genetics | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Prednisone - adverse effects | Anemia - chemically induced | Carboplatin - administration & dosage | Etoposide - administration & dosage | Genotype | Bleomycin - administration & dosage | Doxorubicin - pharmacokinetics | Polymorphism, Genetic | Lomustine - pharmacokinetics | Procarbazine - adverse effects | Vincristine - adverse effects | Cyclophosphamide - pharmacokinetics | Lomustine - administration & dosage | Epirubicin - adverse effects | Etoposide - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - genetics | Lomustine - adverse effects | Neoplasm Proteins - physiology | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bleomycin - pharmacokinetics | Epirubicin - administration & dosage | Glutathione S-Transferase pi - physiology | Hodgkin Disease - enzymology | Vinblastine - pharmacokinetics | Glutathione Transferase - genetics | Vinblastine - adverse effects | Vindesine - adverse effects | Hodgkin Disease - drug therapy | Adult | Dacarbazine - pharmacokinetics | Female | Vindesine - pharmacokinetics | Vincristine - pharmacokinetics | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Prednisone - pharmacokinetics | Vindesine - administration & dosage | Epirubicin - pharmacokinetics | Polymorphism, Single Nucleotide | Doxorubicin - adverse effects | Index Medicus
Journal Article
Cell Biochemistry and Biophysics, ISSN 1085-9195, 3/2015, Volume 71, Issue 2, pp. 1261 - 1265
The purpose of this study is to compare the efficacy and safety of Gefitinib versus VMP in combination with three-dimensional conformal radiotherapy (3D-CRT)... 
Life Sciences | Biochemistry, general | Biotechnology | Three-dimensional conformal radiotherapy | Non-small cell lung cancer | Biophysics and Biological Physics | Brain metastases | Pharmacology/Toxicology | Gefitinib | Cisplatin | Cell Biology | THERAPY | BIOPHYSICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMOTHERAPY | CELL BIOLOGY | Prednisolone - adverse effects | Chemoradiotherapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Brain Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Radiotherapy, Intensity-Modulated - adverse effects | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Melphalan - adverse effects | Vindesine - adverse effects | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Chemoradiotherapy - methods | Radiotherapy, Intensity-Modulated - methods | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - therapy | Melphalan - administration & dosage | Brain Neoplasms - therapy | Quinazolines - adverse effects | Vindesine - administration & dosage | Chemotherapy | Anemia | Gastrointestinal diseases | Lung cancer, Small cell | Metastasis | Comparative analysis | Lung cancer, Non-small cell | Radiotherapy | Cancer | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 8/2008, Volume 100, Issue 15, pp. 1058 - 1067
Background Current recommendations that cancer patients receive a maximum cumulative dose of 900 mg/m2 epirubicin are based on the risk of epirubicin-mediated... 
SURVIVAL | ONCOLOGY | CYCLOPHOSPHAMIDE | DOXORUBICIN | CARDIOVASCULAR-DISEASE | CARDIOTOXICITY | FAILURE | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Heart Failure - physiopathology | Antibiotics, Antineoplastic - adverse effects | Epirubicin - administration & dosage | Tamoxifen - administration & dosage | Cisplatin - administration & dosage | Fluorouracil - administration & dosage | Adult | Female | Retrospective Studies | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Heart - physiopathology | Severity of Illness Index | Disease Susceptibility | Drug Administration Schedule | Risk Factors | Proportional Hazards Models | Neoplasm Recurrence, Local - diagnosis | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Vindesine - administration & dosage | Denmark - epidemiology | Heart - drug effects | Breast Neoplasms - mortality | Methotrexate - administration & dosage | Aged | Heart Failure - chemically induced | Epirubicin - adverse effects | Breast cancer | Dosage and administration | Epirubicin | Drug therapy | Risk factors | Heart | Chemotherapy | Side effects | Toxicity | Oncology | Index Medicus
Journal Article